# A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults.

> **NCT06933043** · PHASE1 · COMPLETED · sponsor: **Navigator Medicines, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** NAV-240
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06933043
- **Lead sponsor:** Navigator Medicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-20
- **Primary completion:** 2025-11-20
- **Final completion:** 2025-11-20
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06933043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06933043, "A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06933043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*